Nexvet Biopharma plc 4
4 · Nexvet Biopharma plc · Filed Nov 24, 2015
Insider Transaction Report
Form 4
Heffernan Mark
Chief Executive Officer
Transactions
- Exercise/Conversion
Option to Purchase Shares
2015-11-23−7,250→ 9,666 total(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)Exercise: $0.13Exp: 2020-11-05→ Ordinary Shares (7,250 underlying) - Exercise/Conversion
Ordinary Shares
2015-11-23$0.13/sh+7,250$906→ 19,334 total
Holdings
- 243,587(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
Ordinary Shares
Footnotes (2)
- [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- [F2]7,250 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 4,833 options to purchase shares will vest and become exercisable on each of 7/1/16 and 7/1/17.